Cytosorbents Corporation (NASDAQ:CTSO) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET
Company Participants
Amy Vogel – Investor Relations
Phillip Chan – Chief Executive Officer
Kathleen Bloch – Chief Financial Officer
Christian Steiner – Executive Vice President-Sales and Marketing and Managing Director-Cytosorbents Europe GmbH
Christopher Cramer – Vice President-Business Development
Efthymios Deliargyris – Chief Medical Officer
Vincent Capponi – Chief Operating Officer and President
Mike Gibson – Principal Co-Investigator-STAR-T
Conference Call Participants
Zach Weiner – Jefferies
Brian Kennedy – Cowen
Sean Lee – H.C. Wainwright
Operator
Good afternoon, and welcome to Cytosorbents Second Quarter 2022 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised the call will be recorded at the company's request.
At this time, I'd like to turn the call over to our moderator, Amy Vogel. Please go ahead, Ms. Vogel.
Amy Vogel
Thank you, and good afternoon. Welcome to the Cytosorbents second quarter 2022 financial and operating results conference call. Joining me today from the company are Dr. Phillip Chan, Chief Executive Officer; Vincent Capponi, Chief Operating Officer and President; Kathleen Bloch, Chief Financial Officer; Dr. Efthymios Deliargyris, Chief Medical Officer; Dr. Christian Steiner, Executive Vice President of Sales and Marketing and Managing Director of Cytosorbents Europe GmbH; and Christopher Cramer, Vice President of Business Development.
Before I turn the call over to Dr. Chan, I'd like to remind listeners that during the call management's prepared remarks may contain forward-looking statements which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore, the company claims protection under Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Actual results may differ from results discussed today and therefore we refer you to a more detailed discussion of these risks and uncertainties in the company's filings with the SEC. Any projections as to the company's future performance represented by management include estimates as of today August 2, 2022 and we assume no obligation to update these projections in the future as market conditions change.
During today's call, we will have an overview presentation covering the operating and financial highlights for the second quarter by management. Following that presentation, we will open the line to your questions during the live Q&A session with the rest of the management team.